ProfileGDS4814 / ILMN_2167252
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 13% 2% 8% 44% 3% 14% 23% 23% 8% 38% 15% 10% 12% 14% 17% 31% 27% 18% 26% 5% 31% 27% 21% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)42.015613
GSM780708Untreated after 4 days (C2_1)37.08862
GSM780709Untreated after 4 days (C3_1)40.60028
GSM780719Untreated after 4 days (C1_2)48.803844
GSM780720Untreated after 4 days (C2_2)38.55053
GSM780721Untreated after 4 days (C3_2)42.211514
GSM780710Trastuzumab treated after 4 days (T1_1)44.241423
GSM780711Trastuzumab treated after 4 days (T2_1)44.279223
GSM780712Trastuzumab treated after 4 days (T3_1)40.59528
GSM780722Trastuzumab treated after 4 days (T1_2)47.22138
GSM780723Trastuzumab treated after 4 days (T2_2)42.474315
GSM780724Trastuzumab treated after 4 days (T3_2)41.040310
GSM780713Pertuzumab treated after 4 days (P1_1)41.702912
GSM780714Pertuzumab treated after 4 days (P2_1)42.192214
GSM780715Pertuzumab treated after 4 days (P3_1)42.953417
GSM780725Pertuzumab treated after 4 days (P1_2)45.885731
GSM780726Pertuzumab treated after 4 days (P2_2)44.915927
GSM780727Pertuzumab treated after 4 days (P3_2)43.07318
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)44.830326
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)39.35485
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)45.739131
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)45.019727
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)43.719921